Trametinib and dabrafenib side effects

Trametinib and dabrafenib are commonly used as combination therapy to treat unresectable or metastatic malignant melanoma with BRAF V600E or V600K mutations. This combination treatment may cause a range of adverse effects. Common side effects include rash, fatigue, nausea, diarrhea, joint pain, fever, headache, etc. Serious adverse reactions may include hypertension, arrhythmia, heart failure, central serous retinal detachment, pneumonia, liver damage, etc. Patients should be regularly monitored and evaluated by their physician while receiving trametinib and dabrafenib to ensure that any adverse reactions are detected and managed promptly. During treatment, you should pay attention to maintaining good health and promptly report any symptoms of discomfort to the doctor so that the treatment plan can be adjusted or necessary measures can be taken.